Skip to main content
Signal8

CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions

$CDTPress releaseMay 6, 2026, 8:30 AM ET

CDT Equity announced that its lead asset AZD5904, licensed from AstraZeneca, has advanced into the Patent Cooperation Treaty phase to secure global intellectual property protection. The drug demonstrated a favorable safety profile with 181 subjects dosed across five Phase 1 studies, targeting idiopathic male infertility and oncology-associated infertility.

Key figures

Drug Name
AZD5904
Phase Of Trial
Phase 1
Subjects dosed
181
Number of studies
5

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.